(Reuters) – Rosetta Genomics Ltd, a maker of diagnostic tests, said Wednesday morning that its key cancer test will be covered by Medicare.
Rosetta said Novitas, the Medicare administrative contractor for its miRview mets2 assay, informed the company that it would cover the test for all Medicare beneficiaries.
The test identifies the tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary.
Rosetta Genomics president and CEO Kenneth Berlin said, “We are particularly pleased with how rapidly we obtained Medicare coverage, as we launched our direct selling effort in the US just one year ago”.
Rosetta is in talks with Novitas and expects a final decision on reimbursement level in the coming weeks, Berlin said.